Full Press Release Details
Pharmaceuticals Inc. Announces Pricing of its Initial Public Offering
New York, August 26, 2025 - Curanex Pharmaceuticals Inc. (Nasdaq: CURX) ("Curanex" or the "Company"), a
developmental stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases, today announced
the pricing of its initial public offering (the "Offering") of 3,750,000 shares of common stock at a public offering price
of $4.00 per share, for gross proceeds of $15 million, before deducting underwriting discounts and offering expenses. The Offering is
being conducted on a firm commitment basis. The Company's shares of common stock are expected to begin trading on the Nasdaq Capital
Market on August 26, 2025, under the ticker symbol "CURX."
Company has granted the underwriters an option, exercisable within 45 days from the close of the Offering,
to purchase up to 562,500 additional shares of common stock at the public offering price, less underwriting discounts and expenses. The
Offering is expected to close on August 27, 2025, subject to customary closing conditions.
Company intends to use the proceeds from the Offering for: (i) the development of our lead product candidate, Phyto-N, for the treatment
of ulcerative colitis; (ii) to conduct FDA-required good laboratory practice ("GLP") toxicology and pharmacokinetic studies
for Phyto-N in ulcerative colitis, (iii) to prepare and submit an Investigational New Drug (IND) application, and (iv) for working capital
and other general corporate purposes.
Securities LLC is acting as the lead underwriter for the Offering, with Pacific Century Securities LLC and Revere Securities LLC acting
as co-underwriters. The Crone Law Group, P.C. is acting as counsel to the Company. Sichenzia Ross Ference Carmel LLP is acting as lead
counsel to the underwriters with respect to the Offering.
registration statement on Form S-1, as amended (File No. 333-282686) relating to the Offering was previously filed with the Securities
and Exchange Commission (the "SEC") and subsequently declared effective by the SEC on August 12, 2025. The Offering is being
made only by means of a prospectus, forming a part of the registration statement. A final prospectus relating to the Offering will be
filed with the SEC and will be available on the SEC's website at www.sec.gov.
copies of the final prospectus related to the Offering may be obtained, when available, from Dominari Securities LLC, 725 5th Avenue,
23rd Floor, New York, NY 10022, or by telephone at (212) 393-4500.
you invest, you should read the final prospectus and other documents the Company has filed or will file with the SEC for more complete
information about the Company and the Offering. This press release shall not constitute an offer to sell or the solicitation of an offer
to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an
offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or
Curanex Pharmaceuticals Inc
Pharmaceuticals Inc is a developmental stage pharmaceutical company headquartered in Jericho, New York, dedicated to discovering and
developing botanical drugs for inflammatory diseases. Its lead candidate, Phyto-N, is a botanical extract from a single plant with proven
anti-inflammatory properties that acts via multiple targets and mechanisms. Phyto-N has a long history of human use, having treated thousands
of patients with inflammatory diseases over 30 years in China, demonstrating favorable tolerability.
Company has validated Phyto-N's effects in animal models of six inflammatory diseases: ulcerative colitis, atopic dermatitis, COVID-19,
diabetes, nonalcoholic fatty liver disease, and gout. The primary indication is moderate to severe ulcerative colitis. The Company will
advance its lead botanical drug candidate, Phyto-N, through FDA-required studies, IND submission, and into Phase I clinical trials.
more information, visit the Company's website at www.curanexpharma.com.
statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to,
the Company's proposed Offering. These forward-looking statements involve known and unknown risks and uncertainties and are based
on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition,
results of operations, business strategy and financial needs, including the expectation that the Offering will be successfully completed.
Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect,"
"anticipate," "aim," "estimate," "intend," "plan," "believe,"
"potential," "continue," "is/are likely to" or other similar expressions. The Company undertakes
no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations,
except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are
reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results
may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results
in the Company's registration statement and in its other filings with the SEC.
more information, please contact:
Liqin Xie, Chief Operating Officer